We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
BPC2.5
BPC-157 Research
Mostly mechanism / observational
20 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most BPC-157 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality studies published 1997–2026 with a typical study size of 17 participants.
Based on 20 studies · 322 total participants
Confidence
Low confidence
By outcome
Tendon, ligament & soft-tissue healingTendon, ligament, muscle, and gut healing shown in animals only; no proven human efficacy and a theoretical tumour-growth concern. · Not established (no human trials)
Mostly mechanism / observational9 studies
Digestive health
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Wound & ulcer healing
Too few graded studies2 studies
Pain & analgesia
Too few graded studies1 study
Active research area
13 studies in the last 5 years
199720112026
1Review2026
In plain English: Further clinical studies will strengthen cytoprotective therapy and, particularly, BPC 157 in complex musculoskeletal and junctional injuries.
Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · Pharmaceuticals (Basel, Switzerland) (2026)
The estimated key was the success of injury recovery amid each agent's direct exogenous administration, alone or with a carrier, locally or systemically, without reliance on complex scaffolds, carriers, or tissue-engineering constructs.
Contrarily, proposed as a cytoprotection mediator, BPC 157 acts alone with a full cytoprotection range, given systemically or locally.
Moreover, without any carrier, BPC 157 acts alone, combining beneficial effects on tendon, ligament, and muscle injuries with osteotendinous, myotendinous, and muscle-to-bone healing.
In plain English: This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. · Current reviews in musculoskeletal medicine (2025)
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine.
Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available.
Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution.
In plain English: This systematic-review examined the effects of BPC-157.
Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · Pharmaceuticals (Basel, Switzerland) (2026)
Systematic review examining BPC-157 efficacy
Published in Pharmaceuticals (Basel, Switzerland) (2026)
Further research warranted to confirm findings
4Review2024
In plain English: Finally, there is nerve-muscle relation in various muscle disturbance counteractions, and nerve-nerve relation in various encephalopathies counteraction, which is also exemplified specifically by the BPC 157 therapy application.
Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, Staresinic M, Sever M, Kokot A, Jurjevic I, Matek D, Coric L, Krezic I, Tvrdeic A, Luetic K, Batelja Vuletic L, Pavic P, Mestrovic T, Sjekavica I, Skrtic A, Seiwerth S. · Pharmaceuticals (Basel, Switzerland) (2024)
This specifically includes counteraction of those disturbances related to their receptors, both blockade and over-activity, destruction, depletion, tolerance, sensitization, and channel disturbances counteraction.
Furthermore, close BPC 157/NO-system relations with the gasotransmitters crossing the cell membrane and acting directly on molecules inside the cell may envisage particular interactions with receptors on the plasma membrane of their target cells.
In plain English: BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.
Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, Amirdelfan K, Burke HW, Christo PJ, Robinson CL. · International journal of molecular sciences (2026)
Studies also report reduced inflammatory cytokine activity, improved microvascular integrity, and beneficial effects on pain modulation through peripheral and dopaminergic mechanisms.
Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration, all suggesting potential therapeutic value without reported major adverse effects.
However, inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials.
In plain English: We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. · Pharmaceuticals (Basel, Switzerland) (2025)
However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.
In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity.
This generated the attention of experts, as BPC 157 has been offered for sale on many websites.
In plain English: This systematic-review examined the effects of BPC-157.
Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday IM, Vukovic V, Oroz K, Coric L, Skoro M, Kavelj I, Zubcic S, Sikiric S, Beketic Oreskovic L, Oreskovic I, Blagaic V, Brcic K, Strbe S, Staresinic M, Boban Blagaic A, Skrtic A, Seiwerth S. · Inflammopharmacology (2024)
These overwhelm current clinical evidence (i.e., ulcerative colitis, phase II, no side effects, and no lethal dose (LD1) in toxicology studies), as BPC 157 therapy effectively combined various tissue healing and lesions counteraction.
In plain English: Thus, to confirm the hypothesis, these BPC 157 conditional, not constitutive effects, in rodent models or in vitro systems (HEK293 cells), mandate expansion of now limited clinical data and mechanisms in human investigated as a translational cytoprotective strategy for complex arrhythmias.
Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · Pharmaceuticals (Basel, Switzerland) (2026)
In vivo, this was across models of hypo-/hyperkalemia, hypermagnesemia, ischemia-reperfusion, myocardial infarction, drug-induced arrhythmias (including local anesthetics), and vascular occlusion.
BPC 157 restores sinus rhythm, normalizes P/QRS/QT intervals, prevents AV block, suppresses VT, attenuates ST-segment changes, and stabilizes heart rate, even when insults are advanced.
Thus, to confirm the hypothesis, these BPC 157 conditional, not constitutive effects, in rodent models or in vitro systems (HEK293 cells), mandate expansion of now limited clinical data and mechanisms in human investigated as a translational cytoprotective strategy for complex arrhythmias.
In plain English: BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. · J Appl Physiol (1985) (2011)
In-vitro / ex-vivo study using rat Achilles-tendon explants and cultured tendon fibroblasts
BPC 157 accelerated fibroblast outgrowth from explants and increased cell survival under H2O2 oxidative stress
Dose-dependently increased fibroblast migration and spreading and induced F-actin formation
In plain English: A complex protective interaction with both alpha-adrenergic (eg, catecholamine release) and dopaminergic (central) systems could be suggested for both intragastric and intraperitoneal BPC 157 administration.
In plain English: A total of 544 articles from 1993 to 2024 were identified. After duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study).
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, et al. · HSS J (2025)
Independent systematic review (PubMed, Cochrane, Embase to June 2024) from an orthopaedic sports-medicine perspective; 36 included studies were 35 preclinical and only 1 clinical
In preclinical models BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries via growth-hormone-receptor, angiogenesis and anti-inflammatory pathways
The single human report was a retrospective study where 7 of 12 patients reported relief >6 months after intra-articular BPC-157 for chronic knee pain — graded level IV/V evidence
In plain English: Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury.
DeFoor MT, Dekker TJ. · Arthroscopy (2025)
Orthopaedic commentary/review on injectable peptides including BPC-157 for athletes and sports performance
Describes the human pharmacokinetic and clinical evidence as very early and scarce
Emphasizes that BPC-157 is unregulated yet readily purchased online, raising safety, ethical and legal concerns
In plain English: Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice and has no reported toxicity.
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L. · Curr Pharm Des (2011)
Review of BPC 157 across the gastrointestinal tract in rat models (esophagus, stomach, duodenum, intestine, liver, pancreas)
Reports protection against alcohol and NSAID lesions and healing of fistulas and short-bowel syndrome in rats
Notes the related sequence PL-14736 (same amino-acid sequence) was used in inflammatory bowel disease clinical trials
In plain English: BPC 157 was concluded to be the most potent angiomodulatory agent, acting through different vasoactive pathways and systems (e.g. NO, VEGF, FAK).
Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M. · Curr Pharm Des (2014)
Review of BPC 157's effects on blood vessels after injury (endothelium damage, clotting, thrombosis, vasoconstriction/dilatation, vasculogenesis, edema)
Describes BPC 157 as a highly potent angiomodulatory agent acting via NO, VEGF and FAK pathways in preclinical models
Explicitly notes blood vessels are 'strongly involved in tumor biology', including neoangiogenesis and metastasis — context for the theoretical tumor concern
In plain English: This small study suggests that intra-articular injection of BPC-157 helps with multiple types of knee pain.
Lee E, Padgett B. · Altern Ther Health Med (2021)
Retrospective chart review of 17 patients given intra-articular BPC 157 (alone or with thymosin-beta-4) for knee pain; 16 followed up by phone
11 of 12 patients (91.6%) who received BPC 157 alone reported significant improvement; 14 of 16 overall reported relief
Uncontrolled and unblinded, self-reported outcomes, no objective imaging or function measures — the authors call for future studies
20Open-Labeln=12 · very small study2024
In plain English: This is the first report of intravesical BPC-157 (10 mg) injection to help patients with moderate to severe interstitial cystitis who did not respond to pentosan polysulfate treatment.
Lee E, Walker C, Ayadi B. · Altern Ther Health Med (2024)
Uncontrolled pilot in 12 women with moderate-to-severe interstitial cystitis who had failed pentosan polysulfate
Single procedure of BPC-157 injection (total 10 mg) around bladder inflammation; outcomes by Global Response Assessment
10 of 12 reported complete resolution and 2 of 12 reported ~80% improvement; no dropouts and no adverse events reported